Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Selena Mimmi

Showing results (31-40 of 38) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 38 results.
Nanoscale|February 10, 2022
A novel phage display based platform for exosome diversity characterizationDomenico Maisano, Selena Mimmi, Vincenzo Dattilo, et al.
Clinical Chemistry and Laboratory Medicine|March 27, 2023
SARS CoV-2 spike protein-guided exosome isolation facilitates detection of potential miRNA biomarkers in COVID-19 infectionsSelena Mimmi, Anna Maria Zimbo, Salvatore Rotundo, et al.
Frontiers in Cell and Developmental Biology|October 4, 2021
Metabolites Profiling of Melanoma Interstitial Fluids Reveals Uridine Diphosphate as Potent Immune Modulator Capable of Limiting Tumor GrowthEleonora Vecchio, Carmen Caiazza, Selena Mimmi, et al.
Frontiers in Bioengineering and Biotechnology|March 30, 2026
New frontiers in porcine atrioventricular node decellularization: preserving extracellular matrix architecture for biological scaffoldsAlice Tomas, Assunta Fabozzo, Domenico Ventrella, et al.
International Journal of Molecular Sciences|July 4, 2012
Design and characterization of a peptide mimotope of the HIV-1 gp120 bridging sheetMarco Schiavone, Giuseppe Fiume, Antonella Caivano, et al.
Scientific Reports|September 8, 2015
Impairment of T cell development and acute inflammatory response in HIV-1 Tat transgenic miceGiuseppe Fiume, Annarita Scialdone, Francesco Albano, et al.
Frontiers in Oncology|August 4, 2022
Survival Risk Scores for Real-Life Relapsed/Refractory Multiple Myeloma Patients Receiving Elotuzumab or Carfilzomib In Combination With Lenalidomide and Dexamethasone as Salvage Therapy: Analysis of 919 Cases Outside Clinical TrialsFortunato Morabito, Elena Zamagni, Concetta Conticello, et al.
Hematological Oncology|May 24, 2022
Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 3-year follow-up of a multicenter, retrospective clinical experience with 319 cases outside of controlled clinical trialsAntonella Bruzzese, Daniele Derudas, Monica Galli, et al.
Pageof 4

Showing results (31-40 of 38) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 38 results.
Nanoscale|February 10, 2022
A novel phage display based platform for exosome diversity characterizationDomenico Maisano, Selena Mimmi, Vincenzo Dattilo, et al.
Clinical Chemistry and Laboratory Medicine|March 27, 2023
SARS CoV-2 spike protein-guided exosome isolation facilitates detection of potential miRNA biomarkers in COVID-19 infectionsSelena Mimmi, Anna Maria Zimbo, Salvatore Rotundo, et al.
Frontiers in Cell and Developmental Biology|October 4, 2021
Metabolites Profiling of Melanoma Interstitial Fluids Reveals Uridine Diphosphate as Potent Immune Modulator Capable of Limiting Tumor GrowthEleonora Vecchio, Carmen Caiazza, Selena Mimmi, et al.
Frontiers in Bioengineering and Biotechnology|March 30, 2026
New frontiers in porcine atrioventricular node decellularization: preserving extracellular matrix architecture for biological scaffoldsAlice Tomas, Assunta Fabozzo, Domenico Ventrella, et al.
International Journal of Molecular Sciences|July 4, 2012
Design and characterization of a peptide mimotope of the HIV-1 gp120 bridging sheetMarco Schiavone, Giuseppe Fiume, Antonella Caivano, et al.
Scientific Reports|September 8, 2015
Impairment of T cell development and acute inflammatory response in HIV-1 Tat transgenic miceGiuseppe Fiume, Annarita Scialdone, Francesco Albano, et al.
Frontiers in Oncology|August 4, 2022
Survival Risk Scores for Real-Life Relapsed/Refractory Multiple Myeloma Patients Receiving Elotuzumab or Carfilzomib In Combination With Lenalidomide and Dexamethasone as Salvage Therapy: Analysis of 919 Cases Outside Clinical TrialsFortunato Morabito, Elena Zamagni, Concetta Conticello, et al.
Hematological Oncology|May 24, 2022
Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 3-year follow-up of a multicenter, retrospective clinical experience with 319 cases outside of controlled clinical trialsAntonella Bruzzese, Daniele Derudas, Monica Galli, et al.
Pageof 4